Related Experiment Videos

Response to comment on "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung

Jacqueline V Aredo¹, Sukhmani K Padda¹, Christian A Kunder²

¹Stanford Cancer Institute, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA, 94305, USA.

Lung Cancer (Amsterdam, Netherlands)

|September 8, 2019

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.

The Lancet. Oncology·2026

Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer.

Nature reviews. Clinical oncology·2026

Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancer.

Cancer discovery·2026

Corrigendum to 'Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System-Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes' [JTO Clinical and Research Reports 6 (2025) 100914].

JTO clinical and research reports·2026

KRAS G12C inhibitor outcomes in advanced non-small cell lung cancer by smoking history, performance status, and KEAP1 mutation status.

Cancer treatment and research communications·2026

Air pollution and the risk of second primary lung cancer among lung cancer survivors: the prospective UK Biobank cohort study.

British journal of cancer·2026

See all related articles